Axcella Health Received A Decision To Grant European Patent Number EP3668499 Titled "Branched-Chain Aminoacids For The Treatment Of Liver Disease"
Portfolio Pulse from Benzinga Newsdesk
Axcella Health has been granted European Patent Number EP3668499, titled 'Branched-Chain Aminoacids For The Treatment Of Liver Disease'. This could potentially open up new markets for the company in Europe.
September 14, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axcella Health's new patent could potentially increase its market reach in Europe, which may positively impact its stock price in the short term.
The granting of a new patent allows Axcella Health to protect its intellectual property and potentially expand its market reach in Europe. This could lead to increased revenues and a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100